Introduction {#s1}
============

Atrial fibrillation is a common cardiovascular disease and is associated with other diseases such as ischemic stroke and heart failure \[[@R01]\]. In recent years, the prevalence of atrial fibrillation has increased because of a concomitant increase in life expectancy \[[@R02]\]. Treatment via an electrophysiologic catheter ablation procedure can be performed for selected patients with atrial fibrillation \[[@R03]\], which may achieve a complete cure in some. Catheter ablation is particularly useful in patients with paroxysmal atrial fibrillation, but less so in those with persistent atrial fibrillation \[[@R04], [@R05]\]. In addition, elderly patients with persistent atrial fibrillation are less likely to receive the procedure for various reasons such as duration of atrial fibrillation, symptoms, activities of daily practice, patient refusal, and limited procedural benefit.

Advanced glycation end products (AGEs) and receptors of AGEs play an important role in the pathophysiology of cardiovascular disease \[[@R06], [@R07]\]. Among the methods used to evaluate AGEs, skin autofluorescence is known to be a simple and reliable marker of AGEs *in vivo*, and recent clinical studies have indicated that skin autofluorescence is significantly associated with cardiovascular disease \[[@R08]-[@R10]\]. However, data regarding the relationship between skin autofluorescence and atrial fibrillation are limited. This cross-sectional study attempted to clarify the clinical significance of skin autofluorescence in elderly patients with long-standing persistent atrial fibrillation.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

In this study, 112 elderly outpatients (age ≥ 65 years) with long-standing persistent atrial fibrillation who were being treated medically at the Hitsumoto Medical Clinic, Yamaguchi, Japan were enrolled between January 2017 and December 2018. Long-standing persistent atrial fibrillation (presence of atrial fibrillation for ≥ 1 year after initiation of rhythm control treatment) is defined by the 2010 Guidelines for the Management of Atrial Fibrillation of the European Society of Cardiology \[[@R11]\]. The patients included 46 (41%) men and 66 (59%) women. The mean patient age was 81 ± 9 years. The study was approved by the Institutional Review Board of the Hitsumoto Medical Clinic (approval number 2017-01) and was conducted in compliance with the Declaration of Helsinki. All patients provided informed consent.

Measurement of skin autofluorescence {#s2b}
------------------------------------

Skin autofluorescence was measured using a commercial device (AGE Reader™; DiagnOptics, Groningen, the Netherlands), as previously described \[[@R12], [@R13]\]. Autofluorescence was defined as the average light intensity per nanometer between 300 and 420 nm. Skin autofluorescence levels were expressed in arbitrary units (AU). All measurements were performed on the volar side of the forearm approximately 10 - 15 cm below the elbow while the patients were in the sitting position. The value of pentosidine, a major component of AGEs, has been previously measured using skin biopsy on the volar side of the forearm and seemed to correlate with skin autofluorescence \[[@R14]\]. Previous reports have established the validity and reliability of skin autofluorescence level measurements using this method in the Japanese population \[[@R13]\].

Evaluation of clinical parameters {#s2c}
---------------------------------

Various clinical parameters were evaluated, including classic risk factors of cardiovascular disease, such as CHADS~2~ score \[[@R15]\], echocardiographic findings, kidney function, brain natriuretic peptide level, high-sensitivity cardiac troponin T (hs-cTnT) level, reactive oxygen metabolites (a marker of oxidative stress), and whole blood passage time (a marker of blood rheology). Obesity was identified using body mass index, calculated as the weight (kg) divided by the squared height (m^2^). Current smoking was defined as smoking at least one cigarette per day over the previous 28 days. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or the use of antihypertensive medication. Dyslipidemia was defined as low-density lipoprotein cholesterol level ≥ 140 mg/dL, high-density lipoprotein cholesterol level ≤ 40 mg/dL, triglyceride level ≥ 150 mg/dL, or the use of lipid-lowering medication. Diabetes mellitus was defined as fasting blood glucose level ≥ 126 mg/dL, hemoglobin A1c (HbA1c) level ≥ 6.5%, or the use of antidiabetic medication or exogenous insulin. Standard echocardiography was performed using the HI VISION Avius ultrasound system (Hitachi Medical Corporation, Tokyo, Japan). Left ventricular wall thickness, left ventricular end-diastolic diameter, left ventricular ejection fraction, and left atrial dimension were measured by echocardiography. The estimated glomerular filtration rate was calculated using the adjusted Modification of Diet in Renal Disease Study equation, which was proposed by the working group of the Japanese Chronic Kidney Disease Initiative \[[@R16]\]. Brain natriuretic peptide levels were measured using the SHIONOSPOT® Reader (Shionogi & Co., Osaka, Japan), and hs-cTnT levels were measured using an hs-cTnT assay (Roche Diagnostics, Basel, Switzerland) \[[@R17]\]. As an *in vivo* oxidative stress marker \[[@R18]\], the reactive oxygen metabolites (d-ROMs) test was performed (Diacron, Grosseto, Italy). Blood rheology was evaluated by measuring whole blood passage time with an MC-FAN HR300 rheometer (MC Healthcare, Tokyo, Japan), as previously reported \[[@R19], [@R20]\].

Statistical analysis {#s2d}
--------------------

In this study, data were expressed as mean ± standard deviation. Comparisons were made using the Student's *t*-test. Simple regression analysis was performed using the Pearson or Spearman rank correlation, and a multivariate analysis was performed using multiple regression. Receiver-operating characteristic curve analysis was performed, and the maximum Youden's index \[[@R21]\] was used to determine the optimal skin autofluorescence cutoff values for high CHADS~2~ scores and high hs-cTnT levels. P \< 0.05 was considered to be statistically significant. StatView J5.0 (HULINKS, Tokyo, Japan) and MedCalc for Windows (MedCalc Software, Ostend, Belgium) software were used for analysis.

Results {#s3}
=======

[Table 1](#T1){ref-type="table"} summarizes the patients' characteristics. The overall mean skin autofluorescence was 2.8 ± 0.5 AU (range, 2.0 - 4.6 AU). Eighty-six patients (77%) had a CHADS~2~ score ≥ 2. [Figure 1](#F1){ref-type="fig"} shows the significant positive correlation between skin autofluorescence and the CHADS~2~ score. [Figure 2](#F2){ref-type="fig"} shows the relationship between skin autofluorescence and the components of the CHADS~2~ score. Skin autofluorescence had a significant correlation with the following components: congestive heart failure, age, diabetes mellitus, and stroke/transient ischemic attack. [Table 2](#T2){ref-type="table"} presents the correlation between skin autofluorescence and various clinical parameters. Smoking status, HbA1c, estimated glomerular filtration rate, brain natriuretic peptide level, hs-cTnT level, d-ROMs test, whole blood passage time, and renin-angiotensin inhibitor use significantly correlated with skin autofluorescence. [Table 3](#T3){ref-type="table"} summarizes the results of multiple regression analysis with skin autofluorescence as a subordinate factor. Explanatory factors were selected by examining the multicollinearity among the variables using stepwise regression; four factors (CHADS~2~ score, whole blood passage time, d-ROMs test, and hs-cTnT level) were identified as independent variables. [Figure 3](#F3){ref-type="fig"} shows the receiver-operating characteristic curve analysis for the detection of high CHADS~2~ scores (≥ 2) and elevated hs-cTnT levels (\> 0.014 ng/mL), based on previous studies \[[@R22], [@R23]\]. The maximum Youden's index indicated that the optimal cutoff values of skin autofluorescence to determine high CHADS~2~ scores and elevated hs-cTnT levels were 2.6 AU and 2.7 AU, respectively.

###### Patient Characteristics

  ------------------------------------ -----------------
  n (male/female)                      112 (46/66)
  Age (years)                          81 ± 9
  Skin autofluorescence (AU)           2.8 ± 0.5
  CHADS~2~ score                       3 ± 2
  Body mass index (kg/m^2^)            22.6 ± 3.5
  Current smoker, n (%)                14 (13)
  Hypertension, n (%)                  75 (67)
    Systolic blood pressure (mm Hg)    131 ± 11
    Diastolic blood pressure (mm Hg)   76 ± 9
  Dyslipidemia, n (%)                  76 (68)
    Total cholesterol (mg/dL)          218 ± 41
    LDL cholesterol (mg/dL)            137 ± 37
    Triglyceride (mg/dL)               127 ± 66
    HDL cholesterol (mg/dL)            55 ± 15
  Diabetes mellitus, n (%)             30 (27)
    Fasting blood glucose (mg/dL)      104 ± 32
    Hemoglobin A1c (%)                 5.9 ± 0.6
  IVSTd (mm)                           9.7 ± 2.2
  LVDd (mm)                            51.5 ± 5.9
  LVEF (%)                             64.4 ± 12.2
  LAD (mm)                             46.9 ± 6.8
  eGFR (mL/min/1.73m^2^ )              51.8 ±19.1
  Log-BNP (pg/mL)                      2.3 ± 0.4
  Log-hs-cTnT (ng/mL)                  -1.8 ± 0.4
  d-ROMs test (U. CARR)                325 ± 82
  WBPT (s)                             59.5 ± 18.3
  Medication                           
    RAS inhibitor, n (%)               61 (55)
    β blocker, n (%)                   23 (21)
    Diuretics, n (%)                   31 (28)
    Statin, n (%)                      35 (31)
    Warfarin/DOAC, n (%)               33 (29)/79 (71)
  ------------------------------------ -----------------

Continuous values are mean ± SD. AU: arbitrary units; LDL: low-density lipoprotein; HDL: high-density lipoprotein; IVSTd: interventricular septal thickness at end-diastole; LVDd: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LAD: left atrial dimension; eGFR: estimated glomerular filtration rate; BNP: brain natriuretic peptide; hs-cTnT: high sensitivity cardiac troponin T; d-ROMs: derivatives of reactive oxygen metabolites; WBPT: whole blood passage time; RAS: renin-angiotensin system; DOAC: direct oral anticoagulant.

![Correlation between skin autofluorescence and CHADS~2~ score. AF: autofluorescence; AU: arbitrary unit.](cr-10-181-g001){#F1}

![Relationship between skin autofluorescence and components of the CHADS~2~ score. Comparisons are between those with and without the following factors: CHF (3.1 ± 0.5 AU vs. 2.7 ± 0.5 AU, respectively, P \< 0.001), age ≥ 75 years (2.9 ± 0.5 AU vs. 2.5 ± 0.4 AU, respectively, P \< 0.001), diabetes mellitus (3.0 ± 0.5 AU vs. 2.7 ± 0.5 AU, respectively, P = 0.019), and stroke/TIA (3.0 ± 0.5 AU vs. 2.7 ± 0.5 AU, respectively, P \< 0.001). \*P = 0.598, \*\*P = 0.019, \*\*\*P \< 0.001. AF: autofluorescence; AU: arbitrary units; CHF: congestive heart failure; TIA: transient ischemic attack.](cr-10-181-g002){#F2}

###### Relationship Between Skin Autofluorescence and Various Clinical Parameters

                                           r       P value
  ---------------------------------------- ------- ----------
  Sex (female = 0, male = 1)               -0.14   0.139
  Body mass index                          -0.13   0.183
  Current smoker (no = 0, yes = 1)         0.24    0.009
  Systolic blood pressure                  0.02    0.852
  Diastolic blood pressure                 -0.03   0.732
  Dyslipidemia (no = 0, yes = 1)           0.02    0.852
  Total cholesterol                        0.02    0.837
  LDL cholesterol                          0.01    0.924
  Triglyceride                             0.05    0.582
  HDL cholesterol                          -0.12   0.190
  Fasting blood glucose                    0.06    0.566
  Hemoglobin A1c                           0.24    0.012
  IVSTd                                    0.02    0.861
  LVDd                                     0.08    0.319
  LVEF                                     0.11    0.251
  LAD                                      0.19    0.051
  eGFR                                     -0.37   \< 0.001
  Log-BNP                                  0.32    \< 0.001
  Log-hs-cTnT                              0.43    \< 0.001
  d-ROMs test                              0.52    \< 0.001
  WBPT                                     0.45    \< 0.001
  RAS inhibitor (no = 0, yes = 1)          -0.16   0.048
  β blocker (no = 0, yes = 1)              0.14    0.137
  Diuretics (no = 0, yes = 1)              0.18    0.062
  Statin (no = 0, yes = 1)                 0.09    0.351
  Anticoagulant (warfarin = 0, DOAC = 1)   -0.04   0.965

r expressed correlation coefficient. LDL: low-density lipoprotein; HDL: high-density lipoprotein; IVSTd: interventricular septal thickness at end-diastole; LVDd: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LAD: left atrial dimension; eGFR: estimated glomerular filtration rate; BNP: brain natriuretic peptide; hs-cTnT: high sensitivity cardiac troponin T; d-ROMs: derivatives of reactive oxygen metabolites; WBPT: whole blood passage time; RAS: renin-angiotensin system; DOAC: direct oral anticoagulant.

###### Multiple Regression Analysis for Skin Autofluorescence

  Explanatory factor   β      P value
  -------------------- ------ ----------
  CHADS~2~ score       0.33   \< 0.001
  WBPT                 0.25   0.002
  d-ROMs test          0.21   0.019
  Log-hs-cTnT          0.19   0.020

R^2^ = 0.47. WBPT: whole blood passage time; d-ROMs: derivatives of reactive oxygen metabolites; hs-cTnT: high sensitivity cardiac troponin T; β: standardized regression coefficient; R^2^: coefficient of determination.

![Receiver-operating characteristic curve analysis for the detection of high CHADS~2~ scores or elevated hs-cTnT levels based on skin autofluorescence. The maximum Youden's index indicated that skin autofluorescence values \> 2.6 AU and \> 2.7 AU are the optimal cutoff points to identify high CHADS~2~ scores (≥ 2) or elevated hs-cTnT levels (\> 0.014 ng/mL), respectively. (a) CHADS~2~ score. (b) hs-cTnT levels. AF: autofluorescence; AU: arbitrary unit; hs-cTnT: high-sensitivity cardiac troponin T; AUC: area under the curve.](cr-10-181-g003){#F3}

Discussion {#s4}
==========

This study aimed to clarify the clinical significance of skin autofluorescence in elderly patients with long-standing persistent atrial fibrillation. The results showed an independent association between skin autofluorescence and CHADS~2~ score, whole blood passage time, hs-cTnT level, and d-ROMs test. In addition, the receiver-operating characteristic curve analysis indicated that the skin autofluorescence values associated with high CHADS~2~ scores and elevated hs-cTnT levels in this study population were \> 2.6 AU and \> 2.7 AU, respectively.

The CHADS~2~ score is a well-known predictor of ischemic stroke in patients with atrial fibrillation \[[@R15], [@R22]\]. Therefore, the independent association between skin autofluorescence and the CHADS~2~ score in this study suggests that increased skin autofluorescence is closely associated with ischemic stroke incidence. Although several physiologic processes are involved in ischemic stroke, vascular dysfunction is one of the main causes. Basic science studies have reported that AGEs or receptors of AGEs can induce vascular cell dysfunction \[[@R24]-[@R26]\]. In addition, clinical studies have indicated a significant association between skin autofluorescence and pulsatility index at the common carotid artery, which reflects vascular resistance in cerebral vessels \[[@R27]\]. Thus, the relation of ischemic stroke and skin autofluorescence can be partly explained by vascular dysfunction in cerebral vessels caused by AGEs. Another mechanism of ischemic stroke is cerebral embolism, which is closely associated with atrial fibrillation. In this clinical setting, thrombosis is known to be produced mainly in the left atrium or left atrial appendage, where impaired blood rheology has been shown to be an important factor \[[@R28], [@R29]\]. Basic science investigations have indicated that AGEs cause impaired blood rheology by mechanisms such as leukocyte-endothelial interaction, activation of platelet aggregation, and increased levels of plasminogen activator inhibitor-1 \[[@R30]-[@R32]\]. Therefore, the independent association between skin autofluorescence and whole blood passage time in this study can be explained by hypothesizing that AGEs play an important role in impairing blood rheology in elderly patients with long-standing persistent atrial fibrillation; consequently, treatment directed at decreasing AGEs may prevent ischemic stroke by improving blood rheology.

Recent clinical studies have shown the clinical importance of hs-cTnT levels as a prognostic factor in patients with atrial fibrillation \[[@R23], [@R33]\]. In addition, hs-cTnT is used as a biomarker to clinically evaluate the severity of myocardial injury. Hofmann et al found a significant relationship between AGE-modified cardiac tissue collagen and skin autofluorescence \[[@R34]\]. They also showed that the AGE level found at the volar side of the forearm seemed to reflect the degree of AGE accumulation in cardiomyocytes. In addition, basic science studies have indicated that AGEs or receptors of AGEs could influence myocardial injury via several pathways \[[@R35], [@R36]\]. Thus, the results of this study and previous ones suggest that AGEs play a crucial role in the progression of myocardial damage in elderly patients with long-standing persistent atrial fibrillation.

Several researchers have emphasized the importance of oxidative stress in the pathogenesis of atrial fibrillation \[[@R37], [@R38]\], and a number of basic science and clinical studies have shown a close association between AGEs or receptors of AGEs and oxidative stress in the heart and arterial vessels \[[@R24], [@R39], [@R40]\]. The results of this study also indicated that the d-ROMs test as an *in vivo* marker of oxidative stress is an important factor for skin autofluorescence. A previous study reported that increased activity of the renin-angiotensin system caused increased oxidative stress or AGE production, and the use of an angiotensin receptor blocker decreased both oxidative stress and receptors of AGEs \[[@R41]\]. This study showed a significantly negative association between angiotensin receptor blocker use and skin autofluorescence, even though angiotensin receptor blocker use was not selected in the multivariate model. Therefore, we have started to intervene by prescribing an angiotensin receptor blocker for patients with high skin autofluorescence; consequently, we expect a reduction in cardiovascular events, including ischemic stroke or heart failure, in elderly patients with long-standing persistent atrial fibrillation.

This study clarified the clinical usefulness of assessing skin autofluorescence to detect a high CHADS~2~ score ≥ 2 or an elevated hs-cTnT level \> 0.014 ng/mL, which are associated with cardiovascular events such as ischemic stroke, heart failure, and coronary artery disease in patients with atrial fibrillation according to previous reports. The receiver-operating characteristic curve analysis indicated that skin autofluorescence values \> 2.6 AU and \> 2.7 AU are the optimal cutoff points to identify a high CHADS~2~ score and an elevated hs-cTnT level, respectively. Therefore, this study indicated that maintaining skin autofluorescence values ≤ 2.6 AU or ≤ 2.7 AU in elderly patients with long-standing persistent atrial fibrillation may decrease cardiovascular events. Genevieve et al performed a study regarding the association between skin autofluorescence and HbA1c levels in patients with diabetes mellitus, and reported that skin autofluorescence was significantly associated with the means of the last five and 10 HbA1c values \[[@R42]\]. In addition, Isami et al reported that lifestyle habits such as physical activity, nonsmoking, adequate sleep, low mental stress level, eating breakfast, and abstaining from sugary foods were independently associated with lower skin autofluorescence \[[@R43]\]. Therefore, it appears that long-term adequate blood glucose control and good lifestyle habits are important to maintain lower skin autofluorescence as early as possible.

Limitations {#s4a}
-----------

This study has several limitations. First, the various medical treatments may have affected the study results. Second, skin autofluorescence was measured in only Japanese patients; previous studies have indicated that skin autofluorescence varies according to race \[[@R44], [@R45]\]. Therefore, the cutoff values for skin autofluorescence found in this study may not apply to non-Japanese populations. Finally, the study design was a single-center cross-sectional study, and the sample size was relatively small. Additional prospective studies, including evaluations of interventional therapies, are required to clarify the clinical significance of skin autofluorescence in elderly patients with long-standing persistent atrial fibrillation.

Conclusions {#s4b}
-----------

In conclusion, the findings of this study showed that skin autofluorescence may be a prognostic factor in elderly patients with long-standing persistent atrial fibrillation. The risk value of skin autofluorescence was considered as 2.6 AU or 2.7 AU. Further prospective studies that include the evaluation of therapies are required to validate the results of this study.
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